HIPAA for clinical research in Latin America
When HIPAA applies to LATAM projects and how it interacts with local data protection laws.
HIPAA and local LATAM legislation
Each LATAM country has its own data protection law: LGPD in Brazil, LFPDPPP in Mexico, Law 25.326 in Argentina, Law 1581 in Colombia, Law 19.628 in Chile. HIPAA applies only when processing identifiable data of US residents or when the sponsor requires it.
Practical convergence: HIPAA technical controls (encryption, audit trail, RBAC) are a minimum that also satisfies most local regulations.
Common LATAM scenarios
- •Trials sponsored by US pharma (common in oncology, cardiology)
- •Collaboration with US universities with NIH funding
- •Centralized analysis in the US for multinational studies
- •Submission to FDA for regional approval of a new drug
Applicable controls
- ✓AES-256 at rest, TLS 1.2+ in transit (meets HIPAA + local standards)
- ✓UTC audit trail timestamps (cross-jurisdictional traceability)
- ✓BAA on Institutional for the US data flow
- ✓Granular RBAC by country/site for multinational studies
FAQ
Do I need to sign a HIPAA BAA if my site is in Mexico?
Depends on data flow. If your US CRO processes PHI originated in Mexico from US residents, yes. If data never leaves Mexico, probably not.
How does HIPAA interact with Mexican LFPDPPP?
They're parallel regulations. LFPDPPP governs processing in Mexico. HIPAA governs when there's flow to the US. Trialinx complies with both with the same tech stack.
Need specific documentation?
Contact us and we'll prepare the package for your ethics committee or DPO.
Contact